GB0412553D0 - Therapeutic agents for the treatment of bone conditions - Google Patents

Therapeutic agents for the treatment of bone conditions

Info

Publication number
GB0412553D0
GB0412553D0 GBGB0412553.0A GB0412553A GB0412553D0 GB 0412553 D0 GB0412553 D0 GB 0412553D0 GB 0412553 A GB0412553 A GB 0412553A GB 0412553 D0 GB0412553 D0 GB 0412553D0
Authority
GB
United Kingdom
Prior art keywords
treatment
bone
therapeutic agents
compounds
bone conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0412553.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen filed Critical University of Aberdeen
Priority to GBGB0412553.0A priority Critical patent/GB0412553D0/en
Publication of GB0412553D0 publication Critical patent/GB0412553D0/en
Priority to SI200530922T priority patent/SI1756046T1/sl
Priority to JP2007514086A priority patent/JP5042015B2/ja
Priority to EP05746683A priority patent/EP1756046B1/en
Priority to US11/628,084 priority patent/US7964643B2/en
Priority to PCT/GB2005/002043 priority patent/WO2005118528A2/en
Priority to DK05746683.1T priority patent/DK1756046T3/da
Priority to DE602005018203T priority patent/DE602005018203D1/de
Priority to AT05746683T priority patent/ATE451350T1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/40—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0412553.0A 2004-06-04 2004-06-04 Therapeutic agents for the treatment of bone conditions Ceased GB0412553D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0412553.0A GB0412553D0 (en) 2004-06-04 2004-06-04 Therapeutic agents for the treatment of bone conditions
SI200530922T SI1756046T1 (sl) 2004-06-04 2005-05-23 Aril alkil sulfonamidi kot terapevtska sredstva za zdravljenje kostnih stanj
JP2007514086A JP5042015B2 (ja) 2004-06-04 2005-05-23 骨状態を治療するための治療薬としてのアリールアルキルスルホンアミド類
EP05746683A EP1756046B1 (en) 2004-06-04 2005-05-23 Aryl alkyl sulfonamides as therapeutic agents for the treatment of bone conditions
US11/628,084 US7964643B2 (en) 2004-06-04 2005-05-23 Aryl alkyl sulfonamides as therapeutic agents for the treatment of bone conditions
PCT/GB2005/002043 WO2005118528A2 (en) 2004-06-04 2005-05-23 Aryl alkyl sulfonamides as therapeutic agents for the treatment of bone conditions
DK05746683.1T DK1756046T3 (da) 2004-06-04 2005-05-23 Arylalkylsulfonamider som terapeutiske midler til behandling af knoglelidelser
DE602005018203T DE602005018203D1 (de) 2004-06-04 2005-05-23 Arylalkylsulfonamide als therapeutische mittel zur behandlung von knochenleiden
AT05746683T ATE451350T1 (de) 2004-06-04 2005-05-23 Arylalkylsulfonamide als therapeutische mittel zur behandlung von knochenleiden

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0412553.0A GB0412553D0 (en) 2004-06-04 2004-06-04 Therapeutic agents for the treatment of bone conditions

Publications (1)

Publication Number Publication Date
GB0412553D0 true GB0412553D0 (en) 2004-07-07

Family

ID=32696703

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0412553.0A Ceased GB0412553D0 (en) 2004-06-04 2004-06-04 Therapeutic agents for the treatment of bone conditions

Country Status (9)

Country Link
US (1) US7964643B2 (https=)
EP (1) EP1756046B1 (https=)
JP (1) JP5042015B2 (https=)
AT (1) ATE451350T1 (https=)
DE (1) DE602005018203D1 (https=)
DK (1) DK1756046T3 (https=)
GB (1) GB0412553D0 (https=)
SI (1) SI1756046T1 (https=)
WO (1) WO2005118528A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0705400D0 (en) * 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
WO2009096198A1 (ja) * 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations 新規ビアリール誘導体
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
AU2015367528B2 (en) 2014-12-17 2020-05-14 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
WO1997016433A1 (en) 1995-10-30 1997-05-09 Smithkline Beecham Corporation Protease inhibitors
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1997033887A1 (en) 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
JP2000515153A (ja) * 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
IL129344A0 (en) * 1996-11-27 2000-02-17 Du Pont Pharm Co Novel integrin receptor antagonists
US6214834B1 (en) 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
IL132630A0 (en) * 1997-05-08 2001-03-19 Smithkline Beecham Corp Protease inhibitors
PT877019E (pt) * 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US6291425B1 (en) * 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
YU47200A (sh) 1998-01-23 2002-11-15 Aventis Pharma Deutschland Gmbh. Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezije
JP4750272B2 (ja) 1998-02-04 2011-08-17 ノバルティス アーゲー マトリックス分解メタロプロテイナーゼを阻害するスルホニルアミノ誘導体
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
EP0960882A1 (en) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
MXPA02009309A (es) * 2000-03-21 2003-03-12 Procter & Gamble Inhibidores de las metaloproteasas n-sustituidas que contienen cadenas laterales carboxiclicas.
WO2001090077A1 (en) * 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU2002228316A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
CN101284773A (zh) 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
GB0126157D0 (en) 2001-10-31 2002-01-02 Univ Aberdeen Therapeutic compounds
US20050227994A1 (en) 2002-03-27 2005-10-13 Shionogi & Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
MXPA05002571A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
DE602004010514T2 (de) 2003-05-07 2008-11-27 The University Court Of The University Of Aberdeen, Aberdeen Ketone und reduzierte ketone als therapeutische mittel zur behandlung von knochenerkrankungen
WO2005058808A1 (en) * 2003-12-15 2005-06-30 Japan Tobacco Inc. N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
WO2005118528A3 (en) 2006-01-26
EP1756046A2 (en) 2007-02-28
WO2005118528A2 (en) 2005-12-15
US20080119555A1 (en) 2008-05-22
DE602005018203D1 (de) 2010-01-21
ATE451350T1 (de) 2009-12-15
JP5042015B2 (ja) 2012-10-03
SI1756046T1 (sl) 2010-04-30
US7964643B2 (en) 2011-06-21
EP1756046B1 (en) 2009-12-09
JP2008501670A (ja) 2008-01-24
DK1756046T3 (da) 2010-04-19

Similar Documents

Publication Publication Date Title
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
MXPA05013366A (es) Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
TW200531689A (en) Therapeutic agents
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
TW200504034A (en) Therapeutic agents
IL182317A0 (en) Cgrp receptor antagonists
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200614996A (en) Antiviral compounds
UA91688C2 (en) Antiviral compounds
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
MY140080A (en) Treatment and prevention of osteoporosis
TW200635903A (en) Therapeutic agents
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
IL180136A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
GB0102672D0 (en) Compounds
EP1546099A4 (en) 3,6-DISUBSTITUTED AZABICYCLO-3.1.0 HEXAN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2006031513A3 (en) Aryl spirolactam cgrp receptor antagonists
PL1696905T3 (pl) Zastosowanie podstawionych 2-aminotetralin do zapobiegawczego leczenia choroby parkinsona
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
TW200633986A (en) Therapeutic agents
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
TW200612969A (en) 3-β-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
GB0412553D0 (en) Therapeutic agents for the treatment of bone conditions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)